Phaseline

Companies › Shanghai Cell Therapy Group

Shanghai Cell Therapy Group: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Super DC Cell Injection
dendritic cell vaccine
–Phase 1Solid Tumor CancerDec 2026
Armored Dendritic Cell Injection
Dendritic cell therapy expressing armored antibodies
–Phase 1Solid CancersDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07146672Super DC Cell InjectionPhase 1Solid Tumor CancerOncologyDec 2026
NCT07479667Armored Dendritic Cell InjectionPhase 1Solid CancersOncologyDec 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.